The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges
Open accessAbstract
Human mesenchymal stem cell (hMSC)-based therapies are of increasing interest in the field of regenerative medicine. As economic considerations have shown, allogeneic therapy seems to be the most cost-effective method. Standardized procedures based on instrumented single-use bioreactors have been shown to provide billion of cells with consistent product quality and to be superior to traditional expansions in planar cultivation systems. Furthermore, under consideration of the complex nature and requirements of allogeneic hMSC-therapeutics, a new equipment for downstream processing (DSP) was successfully evaluated. This mini-review summarizes both the current state of the hMSC production process and the challenges which have to be taken into account when efficiently producing hMSCs for the clinical scale. Special emphasis is placed on the upstream processing (USP) and DSP operations which cover expansion, harvesting, detachment, separation, washing and concentration steps, and the regulatory demands.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Bourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., Redl, H., Rubin, J. P., Yoshimura, K., & Gimble, J. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.006 · Cited by 1,890
Cited by
Challenges in Clinical Development of Mesenchymal Stromal/Stem Cells: Concise Review
Mastrolia, I., Foppiani, E. M., Murgia, A., Candini, O., Samarelli, A. V., Grisendi, G., Veronesi, E., Horwitz, E. M., & Dominici, M. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0044 · Cited by 350
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01855-9 · Cited by 343
Microcarriers for Upscaling Cultured Meat Production
Bodiou, V., Moutsatsou, P., & Post, M. J. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00010 · Cited by 272
Manufacturing cell and gene therapies: challenges in clinical translation
Lee, N. K., & Chang, J. W. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0382 · Cited by 78
“Moreover, increased exposure to FBS can amplify pre-existing safety concerns, including adverse immunological reactions elicited in recipients and the high batch-to-batch variability of FBS [17, 18].”
BackgroundMethods to generate tissue-derived constructs for regenerative medicine applications
Paulo Zambon, J., Atala, A., & Yoo, J. J. (2020) · Methods · doi:10.1016/j.ymeth.2019.09.016 · Cited by 51
Metadata
- Authors
- Jossen, V., van den Bos, C., Eibl, R., & Eibl, D.
- Venue
- Applied Microbiology and Biotechnology
- Published
- 2018-03-22
- Volume
- 102
- Issue
- 9
- Pages
- 3981-3994
- ISSN
- 0175-7598 (ISSN-L)
- 1432-0614
- OpenAlex
- W2801539596
- Cited by
- 208
- References
- 3
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. https://app.cochat.ai/papers/10.1007/s00253-018-8912-x
- The paper
- Jossen, V., van den Bos, C., Eibl, R., & Eibl, D. (2018). Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-018-8912-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.